Recent developments include quarterly earnings transcripts, a revenue surge driven by a licensing deal, product launches, and adoption of AI technology for drug development.

• Jaguar Health released its Q3 2025 earnings transcript detailing operational and financial updates [N1].
• The company reported a revenue surge in Q1 2026 driven by a licensing deal with Woodward Specialty LLC [N2].
• Q4 2025 earnings transcript was published providing further financial and business insights [N3].
• Jaguar launched Neonorm Dog for companion animal gut health in May 2026 [N4].
• Plans to adopt an AI platform to support crofelemer development for intestinal failure treatment were announced in April 2026 [N5].

Jaguar Health has established FDA approval for Mytesi and conditional approval for Canalevia-CA1, with a licensing deal that generated a revenue surge in early 2026. The launch of new products like Neonorm Dog and adoption of AI platforms for drug development indicate active innovation and pipeline expansion. The company’s ability to maintain Nasdaq listing compliance and secure capital supports ongoing operations. These factors suggest potential for growth in niche gastrointestinal health markets and animal health segments.

Jaguar Health has a limited operating history with significant accumulated losses and a stockholders' deficit. The company faces substantial doubt about its ability to continue as a going concern due to cash constraints. It is heavily dependent on a single licensee for revenue and on third-party suppliers and manufacturers, which pose operational risks. Regulatory approval uncertainties, competition, and Nasdaq listing compliance challenges add to the risk profile. Failure to maintain listing or raise additional capital could adversely affect operations and shareholder value.

Jaguar Health's moat is primarily based on its proprietary prescription drug products, including Mytesi and Canalevia-CA1, which have regulatory approvals and patent protections. The company's licensing agreement with Woodward Specialty LLC provides a commercial pathway for these products. However, the company faces competition in its therapeutic areas and depends on third-party suppliers and manufacturers, which may limit its competitive advantage. Its focus on rare disease and gastrointestinal health niches, along with ongoing R&D and intellectual property, contribute to its differentiation but also expose it to regulatory and commercialization risks.

• Limited Operating History and Profitability: Jaguar Health has incurred significant losses and has a limited operating history, which may affect its ability to achieve or sustain profitability [S1].
• Going Concern Uncertainty: The company has substantial doubt about its ability to continue as a going concern due to insufficient cash resources to fund operations through March 2027 [S1].
• Dependence on Licensee: Jaguar Health's future revenue depends heavily on Woodward Specialty LLC's success in commercializing Mytesi and Canalevia-CA1 [S1].
• Regulatory and Commercialization Risks: The company faces risks in obtaining regulatory approvals and achieving market acceptance for its products [S1].
• Supplier and Manufacturing Dependencies: Reliance on third-party suppliers and contract manufacturers creates risks of disruption if contracts are terminated [S1].
• Nasdaq Listing Compliance Risks: The company has faced non-compliance with Nasdaq listing requirements and is under a one-year monitoring period, with risks of delisting if compliance is not maintained [S2].

• Jaguar Health, Inc. is a biopharmaceutical company focused on human and animal health prescription drugs, including gastrointestinal health products [S1].
• The company completed the acquisition of Napo Pharmaceuticals in 2017, which is a key part of its operations [S1].
• Jaguar Health's lead human prescription drug product is Mytesi, approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy [S1].
• The company also commercializes Canalevia-CA1, a conditionally approved prescription drug for chronic idiopathic diarrhea (CID) in dogs, launched in December 2021 [S1].
• Jaguar Health entered into a license agreement on January 12, 2026, granting Woodward Specialty LLC exclusive rights to commercialize Mytesi and Canalevia products in the U.S., receiving upfront and potential milestone payments [S1].
• The company launched Neonorm Dog, a product for companion animal gut health, in May 2026 [N4].
• Jaguar Health plans to adopt an AI platform to support development of crofelemer for treating intestinal failure [N5].
• The company reported a revenue surge in Q1 2026 driven by the licensing deal with Woodward Specialty LLC [N2].
• As of June 30, 2026, Jaguar Health had cash and cash equivalents of $3.79 million and current assets of $17.53 million, with current liabilities of $25.38 million, resulting in a current ratio of 0.69 and a cash ratio of 0.15 [S2].
• The company reported a net loss of $54,000 for the year ended December 31, 2025, and a basic and diluted EPS of -$15.7 per share for Q2 2026 [S2].
• Jaguar Health has a limited operating history and has incurred significant losses, with net comprehensive losses of $54.4 million in 2025 and $39.0 million in 2024, and a stockholders' deficit of $18.7 million as of December 31, 2025 [S1].
• The company faces substantial doubt about its ability to continue as a going concern due to insufficient cash resources to fund operations through March 2027, despite recent capital infusion [S1].
• Jaguar Health depends heavily on the success of Woodward Specialty LLC for commercialization of its main products, Mytesi and Canalevia-CA1, and its future revenue stream is dependent on this relationship [S1].
• The company relies on third-party suppliers and contract manufacturers for active pharmaceutical ingredients and finished products, with risks of disruption if contracts are terminated [S1].
• Jaguar Health faces competition for Mytesi in its approved and planned indications, and regulatory approval risks for current and future products [S1].
• The company has implemented a 1-for-35 reverse stock split effective April 30, 2026, to address Nasdaq listing requirements [S2].
• Jaguar Health was non-compliant with Nasdaq's minimum bid price and publicly held shares requirements but regained compliance with the bid price rule by May 26, 2026, and is subject to a one-year mandatory panel monitor [S2].
• The company continues to monitor and address Nasdaq listing compliance risks, with potential delisting risks if compliance is not maintained [S2].
• Jaguar Health had 47 employees as of December 31, 2025, including 9 with advanced degrees, with teams in research and development, sales, and marketing [S1].